Germany’s health reform highlights growing tension between medicine costs and innovation policy
Metodi Popow/picture alliance
Germany has passed a major health reform package that will significantly tighten medicine spending in Europe’s largest pharmaceutical market. The Statutory Health Insurance Contribution Rate Stabilization Act, introduced by Health Minister Nina Warken, was approved by both houses of parliament and is designed to reduce pressure on Germany’s statutory health insurance system. Without reform, the system was facing a projected deficit of around €19 billion next year.
The package aims to cut more than €100 billion in health insurance costs over four years, with medicines included as one of the main areas of intervention. Drug spending in Germany has almost doubled since 2013 and reached around €58.5 billion last year. Under the new law, mandatory discounts on medicines will rise from 7% to 15.5% next year. Medicines with sales above €100 million will face an additional 1.5% discount, while vaccines will be subject to a separate 9% rebate and price freeze until the end of 2030.
The reform has triggered strong criticism from the pharmaceutical sector. Industry representatives argue that the law sends the wrong signal at a time when Germany and Europe are trying to position themselves as attractive locations for life sciences investment, clinical trials, and pharmaceutical manufacturing. Eli Lilly described the package as an “austerity law,” while Bayer warned that Germany’s pharmaceutical sector could face problems similar to those seen in the automotive industry if policy does not better support innovation and competitiveness.
The German research-based pharmaceutical industry also argues that the final version of the law places a much heavier burden on companies than initially expected. According to estimates cited in the article, the industry’s expected contribution rose from around €1.2 billion to approximately €4.1 billion next year. Some companies have warned that policies focused too heavily on price containment could make Germany less attractive for investment and future launches.
The timing is particularly sensitive because Germany is also at the centre of a wider transatlantic debate on medicine pricing. The United States has launched a trade investigation into Germany’s pricing system, alleging persistent under-reimbursement for innovative medicines. US policymakers argue that low prices in Europe shift too much of the global cost of pharmaceutical innovation onto American patients, while European governments face their own pressure to keep public health systems financially sustainable.
This creates a difficult policy dilemma. On one hand, governments need to control rising health expenditure and protect the affordability of care. On the other, industry warns that lower prices and higher mandatory discounts may affect where companies launch new medicines, conduct trials, and invest in manufacturing or R&D. The concern is that, under US reference pricing policies, a low price in Germany could also reduce prices in the US, making companies more cautious about launching innovative medicines in Europe.
The German government appears aware of this tension. Alongside the cost-containment package, the coalition has pledged to develop a “Germany bonus” for companies that manufacture or conduct research in Germany, potentially giving them preferential treatment on mandatory discounts. An expert panel is expected to present initial proposals by the end of September, although EU state aid rules may complicate the design of such measures.
The reform is therefore not only a national budget measure. It reflects a broader European debate about how to balance access, affordability, industrial strategy, and innovation. As the EU advances files such as the Biotech Act, Critical Medicines Act, and future health funding under the next long-term budget, Germany’s reform shows how difficult that balance may be in practice.
